Evidence map›Paper›PMID 39400652›Full record

ArticleJournal of epidemiology and global health2024

How a Novel Approach of Allergy Call Center Improved the Management of the Anti-COVID Vaccination Campaign in Piedmont: Italy.

Iuliana Badiu, Stefania Nicola, Nicolò Rashidy, Stefano Della Mura, Daniele Tarrini, Virginia Bernardi, Mara Gallicchio, Irene Ridolfi, Elena Saracco, Erika Montabone and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of epidemiology and global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Iuliana Badiu *Department of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Stefania Nicola *Department of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy. stefania.nicola@unito.it.
Nicolò RashidyDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Stefano Della MuraDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Daniele TarriniDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Virginia BernardiDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Mara GallicchioDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Irene RidolfiDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Elena SaraccoDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Erika MontaboneDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Marina MazzolaDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Luca Lo SardoDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Giada GeronazzoDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Ludovica ComolaDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Antonietta ApricenaDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Ilaria VitaliDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Anna QuinternettoDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Lucrezia AlessiDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Federico MeliDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Marzia BoemDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Marcelo TeocchiDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Salvatore SchinoccaDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Maria Carmen Rita AzzolinaHealth Management, Mauriziano Hospital, 10128, Turin, Italy.
Federica CorradiDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Simone NegriniDepartment of Internal Medicine, Clinical Immunology and Translational Medicine Unit, University of Genoa and IRCCS Ospedale Policlinico San Martino, Viale Benedetto XV, 6, 16132, Genoa, Italy.
Giovanni RollaDepartment of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Richard Borrelli *Department of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.
Luisa Brussino *Department of Medical Sciences, Immunology and Allergy Unit, University of Turin, Mauriziano Hospital, 10128, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe anti-COVID vaccination campaign has led to a significant increase in the demand for allergology consultations in patients considered at risk of reaction to anti-COVID-19 vaccines. This study aims to describe the experience of the vaccination campaign held in Piedmont (Italy) which developed a new service of Allergy Call Center (ACC) thus providing for the screening and management of allergy high-risk patients during pandemic. STUDY

designA retrospective analysis was performed on all patients considered at high risk for the development of allergic reactions who were referred by the Immunology and Allergy Unit of Azienda Ospedaliera Ordine Mauriziano in Turin, Italy, between December 2020 and December 2022 and also on ACC consultations.

methodsDuring the COVID-19 pandemic, Piedmont Region instituted the ACC, active from May 10th, 2021 to December 31st 2022, to allow vaccinating doctors to require a telephonic consultation for patients who were considered at high risk for the development of allergic reactions. If further diagnostic evaluations were required, the ACC scheduled a visit with a Consultant of the Unit to better assess the clinical situation of the patient. Furthermore, patients referred by General Practitioners, Occupational Doctors and other consultants were also evaluated by the Unit when required.

resultsDuring the operational period the ACC received a total of 15,865 calls and referred only 336 patients to the unit (27.4% of the total referrals), while General Practitioners referred 499 patients (40.8%), Occupational Doctors referred 61 patients (4.9%), and other consultants referred 326 patients (26.6%).

conclusionsEvaluation and management of a large volume of requests seemed to be facilitated by a proactive framework for screening patients at high risk for allergic reactions as the ones referred by our ACC. This approach led to a prominent decrease in allergological visits to our tertiary care Centre, reducing the waiting times and providing additional support for both patients and healthcare providers, thus allowing the vaccinations to be more easily handled.

Indexed as

Call CentersCOVID-19COVID-19 VaccinesHypersensitivityAdultAgedFemaleHumansItalyMaleMiddle AgedPandemicsReferral and ConsultationRetrospective StudiesSARS-CoV-2COVID-19 VaccinesAllergyAllergy call centerAllergy riskConsultationsCOVID-19SARS-CoV-2 vaccineVaccination campaign

Identifiers

PMID39400652
PMCPMC11652545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.